Loading
institutionsInstitution
Stephenson Cancer Center, OU Health
Oklahoma's only NCI-designated centre, consistently among the top enrollers in NRG gynaecologic trials and home of the SOLO1 and MIRASOL ovarian cancer lead investigator.
Overview
NCI-designated in 2018, Stephenson Cancer Center is the only NCI centre in Oklahoma and serves a state with large American Indian populations. Its gynaecologic oncology group is one of the most productive in the NCI's National Clinical Trials Network: Kathleen Moore led SOLO1, which established olaparib maintenance in newly diagnosed BRCA-mutated ovarian cancer, and MIRASOL, which confirmed the folate receptor alpha ADC mirvetuximab soravtansine in platinum-resistant disease. The Oklahoma Tobacco Research Center and TSET-funded cancer control programmes address the state's high smoking rates, and the centre runs an active phase 1 programme.
Location
Oklahoma City, OK, US
Type
cancer center · University of Oklahoma
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
clinical
OnCo score
#168 · 32 points (0 Newsweek + 8 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to OU Health, including child institutions. 94 works · 1,188 citations · 65% open access · 14% clinical trials · 1% reviews.
Oncology works per year
242022
212023
252024
162025
82026
Most works
- Abdul Rafeh Naqash14 works
- Michelle L. Churchman11 works
- Martin D. McCarter10 works
- Ahmad A. Tarhini9 works
- Susanne M. Arnold9 works
- Igor Puzanov9 works
- John D. Carpten9 works
- George J. Weiner8 works
- Aakrosh Ratan8 works
- Susanna V. Ulahannan8 works
Most cited
- Gynaecologic oncology trials (NRG)
- Ovarian cancer (PARP inhibitors, FRα ADCs)
- Tobacco research
Similar pages
- TrialMIRASOL / GOG-3045
Shares Kathleen N. Moore, Folate receptor alpha, Mirvetuximab soravtansine, Antibody-drug conjugate (ADC).
- PersonUrsula A. Matulonis
Shares Folate receptor alpha, Mirvetuximab soravtansine, PARP, Olaparib.
- TrialSOLO-1
Shares Kathleen N. Moore, PARP, PARP inhibitors, Olaparib.
- PersonJonathan A. Ledermann
Shares PARP, PARP inhibitors, Olaparib, Ovarian cancer.
- CompanyGOG Foundation
Shares Kathleen N. Moore, Mirvetuximab soravtansine, NRG Oncology, National Cancer Institute (NIH).
- PersonAmit M. Oza
Shares PARP, Olaparib, Endometrial cancer, Ovarian cancer.
- TrialA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
cancers
technologies
targets
drugs
ApprovedADC
Mirvetuximab soravtansine · Elahere
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza